What are the new FDA regulations for 2026?

The Quality Management System Regulation, or QMSR, became effective on February 2, 2026. It replaced the previous structure of the Quality System Regulation by incorporating ISO 13485:2016 into 21 CFR Part 820 while retaining additional FDA-specific provisions.

Manufacturers subject to Part 820 must align their quality systems with the incorporated ISO requirements and applicable FDA additions. Important areas include risk-based quality management, design and development, supplier controls, production, validation, complaint handling, recordkeeping, and corrective action. Existing procedures based on the former Quality System Regulation should have been reviewed and mapped to the QMSR rather than assumed to remain compliant without revision.

The change also affects FDA inspection preparation. Companies should ensure that procedures, terminology, quality records, internal audits, management review, and employee training support the new framework. ISO 13485 certification can help demonstrate a structured quality system, but certification does not replace FDA compliance or prevent FDA inspection.

Other developments occurring around 2026—such as updated user fees, electronic-submission requirements, cybersecurity guidance, AI-device policy, or FDA safety-communication programs—should not automatically be described as “new regulations.” Some are fees, guidance documents, submission policies, or agency initiatives rather than binding rules.

Manufacturers should monitor FDA publications throughout 2026 because requirements can also change through final rules, statutory amendments, product-specific regulations, and updated recognized standards.